II. Indications
- See Carbapenem
- Avoid in Pseudomonas and Acinetobacter infections (inactive)
- Complicated Infections
- Community Acquired Pneumonia (limited activity)
- Diabetic Foot Infections
- Acute Intraabdominal and Pelvis Infections
- Complicated Skin and Soft Tissue Infections
- Complicated Urinary Tract Infections
III. Mechanism
- See Carbapenem
IV. Dosing
- Administration
- Administer IV doses over 30 minutes (and do not combine with dextrose solutions)
- Dilute IM doses with Lidocaine (if not allergic)
- FDA approved duration up to 14 days IV and up to 7 days IM
- Adult (and age >12 years)
- Standard Dose: 1 g IM/IV every 24 hours (or 1 hour prior to surgical incision)
- Renal Dosing
- CrCl <30 ml/min: 500 mg IV every 24 hours
- Hemodialysis: 500 mg IV every 24 hours
- Child (3 months to 12 years)
- Dose: 15 mg/kg IV or IM every 12 hours (max total daily dose: 1 gram/day)
V. Drug Interactions
- See Carbapenem
VI. Adverse Effects
- See Carbapenem
VII. Safety
- Unknown safety in pregnancy
- Safe in Lactation
VIII. Resources
IX. References
- LiverTox (2017), accessed online 1/2/2023
- Hamilton (2020) Tarascon Pharmacopeia
- (2012) Presc Lett, Resource #231205, Comparison of CarbapenemAntibiotics
- Zhanel (2007) Drugs: 67(7): 1027-52 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
ertapenem (on 6/21/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ERTAPENEM 1 GRAM VIAL | Generic | $42.39 each |
Ontology: ertapenem (C1120106)
Definition (NCI) | A 1-beta-methyl carbapenem and broad-spectrum beta-lactam antibiotic with bactericidal property. Ertapenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, in particular PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition results in a weakening and subsequent lysis of the cell wall leading to cell death of Gram-positive and Gram-negative aerobic and anaerobic pathogens. This agent is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, cephalosporinases and extended-spectrum beta-lactamases. |
Concepts | Antibiotic (T195) , Organic Chemical (T109) |
MSH | C446479 |
SnomedCT | 385574002, 396346003 |
LNC | LP33356-4, MTHU016193 |
English | (4R,5R,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-yl)sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, ertapenem [Chemical/Ingredient], ertapenem, Ertapenem (product), Ertapenem (substance), Ertapenem, ERTAPENEM |
Spanish | ertapenem (producto), ertapenem (sustancia), ertapenem |